Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects

Nardi-Agmon, Inbar; Peled, Nir

doi:10.2147/lctt.s104205

Cited by 68 publications

(56 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therapeutic stratification would be expected to increase the survival rate (27,28). Although certain targeted drugs, including epidermal growth factor receptor tyrosine-kinase and anaplastic lymphoma kinase/proto-oncogene tyrosine-protein kinase ROS inhibitors (29) have been used in the clinic, their cost (30) and acquired resistance (31) remain challenges for their use in the treatment of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

et al. 2017

View full text Add to dashboard Cite

Abstract. L-securinine is a natural product extracted and isolated from the leaf of dried Securinega suffruticosa. The aim of the present study was to explore the effects of L-securinine on proliferation, and the methylation profile of the dickkopf-related protein 1 (DKK1) gene in human lung cancer cells and fibroblasts. L-securinine was extracted, isolated and the structure was identified. The cytotoxicity of L-securinine in A549 cells was evaluated by Cell Counting Kit-8 assays. The expression and DNA methylation profile of DKK genes was analyzed by reverse transcription-quantitative polymerase chain reaction and bisulfite sequencing polymerase chain reaction, respectively. L-securinine inhibited the proliferation of lung cancer cells; the half-maximal inhibitory concentration values were 8.92, 4.73 and 3.81 µg/ml, at 24, 36 and 48 h post-treatment, respectively. DKK1, 2 and 3 expression was significantly increased in A549 cells compared with HLF-a cells. L-securinine induced the downregulation of DKK1 in A549 cells in a dose-dependent manner and induced methylation changes at CpG sites in the DKK1 promoter region. L-securinine may be a potential anticancer drug that mediates its effects by altering DKK1 gene methylation.

show abstract

Section: Discussionmentioning

confidence: 99%

L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…As part of the on-going efforts to standardise breath collection the RECIVA Breath sampler has been developed enabling multi-centre clinical trials regardless of analytical platform. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 A c c e p t e d M a n u s c r i p t Summary of studies of exhaled breath in lung cancer 141,142 .…”

Section: Clinical Research To Datementioning

confidence: 99%

The potential of breath analysis to improve outcome for patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

Lung cancer remains the most common cause of cancer related death in both the UK and USA. Development of diagnostic approaches that have the ability to detect lung cancer early are a research priority with potential to improve survival. Analysis of exhaled breath metabolites, or volatile organic compounds (VOCs) is an area of considerable interest as it could fulfil such requirements. Numerous studies have shown that VOC profiles are different in the breath of patients with lung cancer compared to healthy individuals or those with non-malignant lung diseases. This review provides a scientific and clinical assessment of the potential value of a breath test in lung cancer. It discusses the current understanding of metabolic pathways that contribute to exhaled VOC production in lung cancer and reviews the research conducted to date. Finally, we highlight important areas for future research and discuss how a breath test could be incorporated into various clinical pathways.

show abstract

“…Detection of exhaled volatile compounds may be very useful in the screening of certain malignancies and in the follow-up of inflammatory lung diseases 29 . Proteomic and metabolomic techniques of breath condensate have a promising role in the diagnosis and control of…”

Section: -Biomarkers and Biological Monitoringmentioning

confidence: 99%

Current and Future Respiratory Medicine Challenges: Insights from a Barcelona Respiratory Network Foundation Retreat in Barcelona in 2017

Dorca¹,

Agustí²,

Monsó³

2018

BRN

View full text Add to dashboard Cite

On a global level, respiratory diseases impose a major worldwide health burden affecting millions of people. Respiratory diseases are not only very common but present a great challenge to human health and a productive economy. Prevention, control and cure of these conditions are among the most cost-effective interventions to be taken within a healthcare system and must be a priority for researchers as well as for health authorities. Today, many novel technologies can potentially improve the diagnosis and control of numerous diseases, and the present challenge is how they can be quickly developed and implemented. This review summarises the main conclusions of a Barcelona Respiratory Network (BRN) Foundation Retreat held last year in Barcelona. The debate was structured around four distinct sections: 1) trends that impact current society; 2) foreseeable changes in the field of respiratory health; 3) challenges for the future of healthcare systems; and, 4) future biomedical research trends in respiratory medicine. (BRN Rev. 2018;4(3):214-27)

show abstract

Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects

Cited by 68 publications

References 57 publications

L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation

The potential of breath analysis to improve outcome for patients with lung cancer

Current and Future Respiratory Medicine Challenges: Insights from a Barcelona Respiratory Network Foundation Retreat in Barcelona in 2017

Contact Info

Product

Resources

About